full
border
#666666
http://www.lennonsearch.com/wp-content/themes/smartbox-installable/
https://www.lennonsearch.com/
#26ADE4
style3
Over 25 Years Of Expertise
828-403-6096

Archive for February, 2015

25
Feb

Few could fault the United Kingdom for aiming too low. Having seen its CNS R&D chops whittled away by Big Pharma cuts, the U.K. government has decided the best way out of the mire is to take aim at one of the trickiest fields of all with a multimillion-pound dementia R&D investment fund. …read more […]

25
Feb

Juno Therapeutics enjoyed one of the hottest IPOs in the biotech industry not so long ago, cashing in on its CAR-T rep. So it’s no wonder that its top executives are enjoying some bonus pay these days. …read more Source: On a winning streak, Juno’s top execs snag bonus pay     

24
Feb

Everybody sees something different when they look at Eli Lilly, which has recently dropped out of the top 10 pharma group. A number of analysts, some with good reason to shine up to CEO John Lechleiter, see a company that has hit bottom and is on the comeback trail, with new drug approvals to help […]

23
Feb

Going against the advice of its independent experts, the FDA approved Novartis’ new blood cancer drug for patients with particularly deadly forms of multiple myeloma, looking past some serious safety issues and concerns about the drug’s supporting data. …read more Source: Novartis bags a surprise approval for the blood cancer-treating panobinostat     

default
Loading posts...
link_magnifier
#5C5C5C
off
fadeInDown
loading
#5C5C5C
off